Who Paid My Doc Search
Menu
Organisation paid for research Program year 2025 Source: CMS Open Payments

Quest Research Institute LLC

Neither a doctor nor a teaching hospital

Research payments

$8,312,927

480 payments

Through program year 2025, Quest Research Institute LLC is reported as receiving $8,312,927 in research payments, across 480 payments.

By program year

5 rows
Year Kind Amount Payments
2025 Research $4,396,362 211
2024 Research $1,548,587 148
2023 Research $1,614,651 75
2022 Research $535,888 29
2021 Research $217,440 17

Breakdown

Who paid Research payments · program years 2021–2025
  1. Genentech, Inc. $2,247,776 111 payments
  2. Eli Lilly and Company $1,332,195 13 payments
  3. Sanofi Pasteur Inc. $1,273,975 35 payments
  4. H. Lundbeck A S $1,174,092 84 payments
  5. AstraZeneca Pharmaceuticals LP $467,835 3 payments
  6. Janssen Research & Development, LLC $448,238 18 payments
  7. Takeda Pharmaceuticals U.S.A., Inc. $427,867 73 payments
  8. AbbVie, Inc. $323,656 36 payments
  9. Amylyx Pharmaceuticals, Inc. $285,599 79 payments
  10. Roche TCRC, Inc. $185,170 16 payments
Studies the money was for Research payments · program years 2021–2025
  1. Pom Study of Brain Shuttle Gantenerumab in Early Ad $878,768 42 payments
  2. Lu Af28996 in Participants With Parkinson's Disease (PD) $651,554 5 payments
  3. A Trial of Amlenetug (Lu AF82422) in Participants With Multiple System Atrophy (MSA) (MASCOT) $522,538 79 payments
  4. A Study of Different Donanemab (Ly3002813) Dosing Regimens in Adults With Early Alzheimer's Disease (Trailblazer-Alz 6) $476,271 3 payments
  5. A Phase I/II, Randomized, Modified Double-blind Study to Investigate the Safety and Immunogenicity of Different Doses of Hexavalent Influenza mRNA HA + mRNA NA Vaccine in Adult Participants 50 Years of Age and Older $471,755 15 payments
  6. A Phase 1/2, Randomized, Modified Double-blind, Placebo-controlled, Multi-center, Dose Escalating Study to Evaluate the Safety and Immunogenicity of a Pandemic Flu H5 mRNA Vaccine in Healthy Adults Aged 18 Years and Older $465,114 11 payments
  7. A Multicenter, Randomized, Placebo-Controlled, Double-Blind, Parallel-Group Study, to Assess Efficacy, Safety and Immunogenicity of JNJ-64042056, a Phosphorylated Tau Targeted Active Immunotherapy, in Participants with Preclinical Alzheimer's Disease $448,238 18 payments
  8. A Phase 2B Efficacy Safety Trial of Prasinezumab in Patients With Early Parkinson S Disease $439,030 36 payments
  9. Alzheimer's Disease Master Pre Screener $384,139 12 payments
  10. A Randomized, Double-blind, Placebo-Controlled, Phase 2 Study to Evaluate the Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of Intravenous TAK-341 in Subjects With Multiple System Atrophy $373,209 56 payments

What you are looking at

A noncovered recipient is an organisation paid for research that is neither an individual clinician nor a teaching hospital — typically a contract research organisation, a foundation or a trial site network. They receive 81% of all reported research money, which is why they appear here at all.

Provenance

Source: CMS Open Payments · through program year 2025

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record